Author:
Carkaci Derya,Nielsen Xiaohui C.,Fuursted Kurt,Skov Robert,Skovgaard Ole,Trallero Emilio P.,Lienhard Reto,Åhman Jenny,Matuschek Erika,Kahlmeter Gunnar,Christensen Jens J.
Abstract
Background:
Aerococcus urinae and Aerococcus sanguinicola are relatively newcomers and emerging organisms in clinical and microbiological practice. Both species have worldwide been associated with urinary tract infections. More rarely cases of bacteremia/septicemia and infective endocarditis have been reported. Treatment options are therefore important. Just recently, European recommendations on susceptibility testing and interpretive criteria have been released.
Objective:
In this investigation 120 A. urinae and A. sanguinicola isolates were tested for susceptibility to six antimicrobial agents: Penicillin, cefotaxime, meropenem, vancomycin, linezolid, and rifampicin.
Methods:
Three susceptibility testing methods were used; disk diffusion according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST) standardized disk diffusion methodology and MIC determination with Etest and broth microdilution (BMD). All testing was performed with EUCAST media for fastidious organisms.
Results:
Data obtained in this study were part of the background data for establishing EUCAST breakpoints. MIC values obtained by Etest and BMD were well correlated with disk diffusion results.
Conclusion:
All isolates were found susceptible to all six antimicrobial agents: penicillin, cefotaxime, meropenem, vancomycin, linezolid, and rifampicin.
Publisher
Bentham Science Publishers Ltd.
Subject
General Immunology and Microbiology
Reference22 articles.
1. Rasmussen M.
Aerococcus: An increasingly acknowledged human pathogen.
Clin Microbiol Infect
2016;
22
(1)
: 22-7.
2. Sunnerhagen T, Nilson B, Olaison L, Rasmussen M.
Clinical and microbiological features of infective endocarditis caused by aerococci.
Infection
2016;
44
(2)
: 167-73.
3. Shelton-Dodge K, Vetter EA, Kohner PC, Nyre LM, Patel R.
Clinical significance and antimicrobial susceptibilities of Aerococcus sanguinicola and Aerococcus urinae.
Diagn Microbiol Infect Dis
2011;
70
(4)
: 448-51.
4. Lupo A, Guilarte YN, Droz S, Hirzel C, Furrer H, Endimiani A.
In vitro activity of clinically implemented β-lactams against Aerococcus urinae: Presence of non-susceptible isolates in Switzerland.
New Microbiol
2014;
37
(4)
: 563-6.
5. Christensen JJ, Kilian M, Fussing V, et al.
Aerococcus urinae: Polyphasic characterization of the species.
APMIS
2005;
113
(7-8)
: 517-25.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献